menu
    • menu

    Company profile for Reata Pharmaceuticals

    Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

    Virtual Booth

    Contact Supplier

    With Virupaksha, you get a quality product with on-time delivery.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2025-11-24

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    ChemExpress delivers end-to-end CRO & CDMO solutions for small molecules, biologics & new modalities with ICH-grade quality.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Reata’s mission is to identify, develop, and commercialize novel therapeutics to address serious and life-threatening diseases with few or no approved therapies by targeting molecular pathways that regulate cellular metabolism and inflammation. Our lead product candidates, bardoxolone methyl and omaveloxolone, are Nrf2 activators, previously referred to as antioxidant inflammation modulators (AIMs). Nrf2 is a transcription f...
    Reata’s mission is to identify, develop, and commercialize novel therapeutics to address serious and life-threatening diseases with few or no approved therapies by targeting molecular pathways that regulate cellular metabolism and inflammation. Our lead product candidates, bardoxolone methyl and omaveloxolone, are Nrf2 activators, previously referred to as antioxidant inflammation modulators (AIMs). Nrf2 is a transcription factor for restoring mitochondrial function, reducing oxidative stress, and resolving inflammation.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Reata PharmaceuticalsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    2801 Gateway Drive, Suite 150 Irving, Texas 75063
    Telephone
    Telephone
    (972) 865-2219
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.reatapharma.com/home/default.aspx
    Linkedin
    Linkedin
    https://www.linkedin.com/company/reata-pharmaceuticals/?originalSubdomain=in
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    DDL Conference

    Not Confirmed

    envelop Contact Supplier

    DDL Conference

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Biogen axes asset from $7.3B buyout, plus Alzehimer’s
    Biogen axes asset from $7.3B buyout, plus Alzehimer’s

    13 Feb 2025

    // FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/biogen-enlists-royalty-pursuit-lupus-crown-securing-250m-fund-phase-3-program

    FIERCE BIOTECH
    13 Feb 2025
    Share Share
    Biogen lays off 100-plus Reata staffers
    Biogen lays off 100-plus Reata staffers

    12 Oct 2023

    // Fraiser Kansteiner FIERCE PHARMA

    https://www.fiercepharma.com/pharma/biogen-starts-layoffs-newly-acquired-reata-113-set-lose-positions

    Fraiser Kansteiner FIERCE PHARMA
    12 Oct 2023
    Share Share
    Reata Pharmaceuticals Stockholders Approve Merger Transaction With Biogen Inc.
    Reata Pharmaceuticals Stockholders Approve Merger Transaction With Biogen Inc.

    21 Sep 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20230921976967/en

    BUSINESSWIRE
    21 Sep 2023
    Share Share
    How Biogen courted Reata for $7.3B—and outbid a competitor
    How Biogen courted Reata for $7.3B—and outbid a competitor

    15 Aug 2023

    // Eric Sagonowsky FIERCE PHARMA

    https://www.fiercepharma.com/pharma/how-biogen-outbid-rival-pharma-claim-reata-its-own-73b

    Eric Sagonowsky FIERCE PHARMA
    15 Aug 2023
    Share Share
    Biogen to buy Reata for $6.5 bln to bulk up rare disease portfolio
    Biogen to buy Reata for $6.5 bln to bulk up rare disease portfolio

    29 Jul 2023

    // HEALTH ET

    https://health.economictimes.indiatimes.com/news/pharma/biogen-to-buy-reata-for-6-5-bln-to-bulk-up-rare-disease-portfolio/102220586

    HEALTH ET
    29 Jul 2023
    Share Share
    Biogen to Acquire Reata Pharmaceuticals
    Biogen to Acquire Reata Pharmaceuticals

    28 Jul 2023

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2023/07/28/2713028/0/en/Biogen-to-Acquire-Reata-Pharmaceuticals.html

    GLOBENEWSWIRE
    28 Jul 2023
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search